These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24982227)

  • 21. [Do we really need new antibiotics?].
    Putensen C
    Dtsch Med Wochenschr; 2014 Nov; 139 Suppl 3():S83-4. PubMed ID: 25429536
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit.
    Jamal W; Salama M; Dehrab N; Al Hashem G; Shahin M; Rotimi VO
    J Hosp Infect; 2009 Jul; 72(3):234-42. PubMed ID: 19493588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies.
    Montravers P; Bassetti M; Dupont H; Eckmann C; Heizmann WR; Guirao X; García MS; Capparella MR; Simoneau D; Bodmann KF
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii15-24. PubMed ID: 23772042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
    Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
    Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
    Morfin-Otero R; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Initial use of tigecycline in Argentina].
    Curcio D; Fernández F; Duret F
    Rev Chilena Infectol; 2007 Dec; 24(6):497-9. PubMed ID: 18180827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.
    Tasina E; Haidich AB; Kokkali S; Arvanitidou M
    Lancet Infect Dis; 2011 Nov; 11(11):834-44. PubMed ID: 21784708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens.
    Jean SS; Hsueh PR
    Expert Opin Pharmacother; 2011 Oct; 12(14):2145-8. PubMed ID: 21895553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia.
    Somily AM; Al-Khattaf AS; Kambal AM
    Saudi Med J; 2010 Jan; 31(1):18-24. PubMed ID: 20062893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance?
    Fraise AP
    J Infect; 2006 Nov; 53(5):293-300. PubMed ID: 16876253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.
    Garrison MW; Mutters R; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp.
    Eser OK; Ergin A; Tunçkanat F; Hasçelik G
    New Microbiol; 2008 Oct; 31(4):535-42. PubMed ID: 19123310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit.
    Swoboda S; Ober M; Hainer C; Lichtenstern C; Seiler C; Wendt C; Hoppe-Tichy T; Büchler M; Weigand MA
    J Antimicrob Chemother; 2008 Mar; 61(3):729-33. PubMed ID: 18222953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients enrolled in randomised clinical trials are not representative of critically ill patients in clinical practice: observational study focus on tigecycline.
    Zimmermann JB; Horscht JJ; Weigand MA; Bruckner T; Martin EO; Hoppe-Tichy T; Swoboda S
    Int J Antimicrob Agents; 2013 Nov; 42(5):436-42. PubMed ID: 24055255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
    Eckmann C; Montravers P; Bassetti M; Bodmann KF; Heizmann WR; Sánchez García M; Guirao X; Capparella MR; Simoneau D; Dupont H
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii25-35. PubMed ID: 23772043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in antibacterial therapy against emerging bacterial pathogens.
    Pournaras S; Iosifidis E; Roilides E
    Semin Hematol; 2009 Jul; 46(3):198-211. PubMed ID: 19549574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.